Fig. 6: Transfer of DXM/lactoferrin PMN-MDSC relieved bleomycin-induced interstitial pneumonia without promoting tumor development. | Communications Biology

Fig. 6: Transfer of DXM/lactoferrin PMN-MDSC relieved bleomycin-induced interstitial pneumonia without promoting tumor development.

From: Dexamethasone and lactoferrin induced PMN-MDSCs relieved inflammatory adverse events of anti-cancer therapy without tumor promotion

Fig. 6: Transfer of DXM/lactoferrin PMN-MDSC relieved bleomycin-induced interstitial pneumonia without promoting tumor development.

a Diagram of the experimental design. BLM sulfate (2 U/kg) was administered intratracheally to wild type (WT) mice through tracheotomy under isoflurane anesthesia 14 d after tumor implantation, and tested on day 28. For PMN-MDSC transfer experiments, 1 × 106 cells of Con PMN-MDSC, DXM/lactoferrin (D/L) PMN-MDSC, tumor PMN-MDSC, or vehicle control (PBS) was administered i.v. before BLM challenge on day 13 every other day three times. DXM was administered at 1 mg/kg/day from day 12 through day 16 in the indicated group. b Total cell counts in the bronchoalveolar lavage fluid (BALF). c Histopathological scores. d Representative images of hematoxylin and eosin-stained sections of the lungs. e Collagen content in the lungs. f Tumor growth. g Typical example of flow cytometric analysis and h statistical analysis of PMN-MDSCs in the lungs (n = 6 biologically independent animals). Error bars displayed the mean and standard deviation.

Back to article page